# Sensible Biotechnologies

> Biotechnology company designing and manufacturing naturally modified mRNA inside engineered living cells.

## Why it is interesting

Its biological manufacturing approach could change the purity, cost and performance profile of mRNA, but still needs reproducible scale and regulatory validation.

## Profile

- **Latest funding:** Series A equity plus non-dilutive funding — $47M package, including up to $20M non-dilutive (October 6, 2026)
- **Latest known valuation:** Undisclosed (October 6, 2026)
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences, deep-tech, ai-ml
- **Coverage:** full
- **Last updated:** 2026-10-08T02:35:00Z
- **Latest funding investors:** Oxford Science Enterprises, OTB Ventures, In-Q-Tel, Recode Ventures, Isomer Capital, Y Combinator

## Key facts

- Announced a $47M package combining Series A equity with up to $20M in non-dilutive funding.
- The company did not separately disclose the Series A amount; Axios reported $27M.

## Funding history

- Series A equity plus non-dilutive funding · $47M package, including up to $20M non-dilutive · October 6, 2026
  Source: https://www.sensible.bio/

## Investors in our directory

- https://venturecapitaltracker.com/fund/oxford-science-enterprises

## Related articles

- https://venturecapitaltracker.com/2026-namespace-clockwork-arboretum-200m-funding-roundup

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 8, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/sensible-biotechnologies